1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Chronic venous ulceration (CVU) Market Overview at a Glance

4.1 Market Share (%) Distribution of Chronic venous ulceration (CVU) in 2017
4.2 Market Share (%) Distribution of Chronic venous ulceration (CVU) in 2030

5 Disease Background and Overview: Chronic venous ulceration (CVU)

5.1 Symptoms
5.2 Classification
5.3 Pathophysiology
5.4 Pathogenesis
5.5 Prognostic Indicators
5.6 Clinical Characteristics
5.7 Prevention
5.8 Differential diagnosis
5.9. Diagnosis
5.9.1. Trendelenburg test
5.9.2. Perthes test
5.9.3. Doppler auscultation
5.9.4. Leg venography
5.9.5. Contrast?enhanced computed tomography of the leg
5.9.6. Color Doppler echography of the leg
5.9.7. Magnetic resonance venography of the leg
5.9.8. Venous plethysmography of the lower leg
5.9.9. Ankle-brachial pressure index (ABI or ABPI)

6 Recognized Establishments

7 Treatment

7.1 Conservative Management
7.1.1 Compression therapy
7.1.2 Leg Elevation
7.1.3 Dressings
7.2 Mechanical Treatment
7.3 Medications
7.3.1 Pentoxifylline
7.3.2 Aspirin
7.3.3 Micronized purified flavonoid fraction.
7.3.4 Iloprost
7.3.5 Oral Zinc
7.3.6 Antibiotics/Antiseptics
7.3.7 Hyperbaric Oxygen Therapy
7.4 Recombinant Growth Factors
7.5 Wound Care
7.6 Surgical Management
7.6.1 Debridement
7.6.2 Skin Grafting
7.6.3 Surgery for Venous Insufficiency
7.6.4 Venous surgery
7.6.5 Sclerotherapy
7.6.6 Subfascial Endoscopic Perforator Surgery
7.7 Prevention of Venous Ulcer Recurrence
7.8 New Technologies

8 Compression therapy after invasive treatment of superficial veins of the lower extremities: Clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American College of Phlebology, Society for Vascular Medicine, and International Union of Phlebology (2019)

8.1 Compression versus no compression after thermal ablation or stripping of the saphenous veins
8.1.1 Compression after thermal ablation or stripping of the saphenous veins
8.1.2 Dose of compression after thermal ablation or stripping of the varicose veins
8.2 Short-term compression (<2 weeks) versus long-term compression after thermal ablation
8.2.1 Duration of compression therapy after thermal ablation or stripping of the saphenous veins.
8.3 Compression after sclerotherapy
8.3.1 Compression therapy after sclerotherapy.
8.3.2 Duration of compression therapy after sclerotherapy
8.4 Compression after treatment of superficial veins in patients with venous leg ulcers
8.4.1 Compression after superficial vein treatment in patients with a venous leg ulcer
8.4.2 Compression after superficial vein treatment in patients with a mixed arterial and venous leg ulcer

9 Evidence?based (S3) guidelines for diagnostics and treatment of venous leg ulcers- European Dermatology Forum (2016)

9.1 Diagnostic Recommendations
9.2 Recommendations for compression therapy
9.3 Recommendations for treatment of wounds
9.4 Recommendations for invasive treatment
9.5 Recommendations for oral medication
9.6 After treatment recommendations
9.7 Lifestyle recommendations

10 Wound healing society - Guidelines for venous ulcers (2015)

10.1 Guidelines for the diagnosis of lower extremity venous ulcers
10.2 Guidelines for lower extremity compression for treatment of venous ulcers
10.3 Guidelines for infection control in the treatment of venous ulcers
10.4 Guidelines for wound bed preparation in the treatment of venous ulcers
10.5 Guidelines for dressings in the treatment of venous ulcers
10.6 Guidelines for surgery in the treatment of venous ulcers
10.7 Guidelines for the use of adjuvant agents (topical, device, and systemic) in the treatment of venous ulcers
10.7.1 Topical Agents
10.7.2 Devices
10.7.3 Systemic Agents
10.8 Guidelines for long-term maintenance in the treatment of venous ulcers

11 Epidemiology and Patient Population

11.1 Key Findings
11.2 7MM Prevalent Population of Venous Ulcers
11.3 7MM Diagnosed Prevalent Population of Venous Ulcers
11.4 7MM Diagnosed Prevalent Population of Chronic Venous Ulcers (CVU)

12 7MM Epidemiology of Chronic Venous Ulceration (CVU)

12.1.1 Assumptions and Rationale
12.2 United States
12.2.1 Prevalent Cases of Venous Ulcers in the United States
12.2.2 Diagnosed Prevalent Cases of Venous Ulcers in the United States
12.2.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in the United States
12.2.4 Type-specific Distribution of Venous Ulcers in the United States
12.2.5 Gender-specific Distribution of Venous Ulcers in the United States
12.2.6 Age-specific Distribution of Venous Ulcers in the United States
12.3 EU5 Countries
12.4 Germany
12.4.1 Prevalent Cases of Venous Ulcers in Germany
12.4.2 Diagnosed Prevalent Cases of Venous Ulcers in Germany
12.4.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Germany
12.4.4 Type-specific Distribution of Venous Ulcers in Germany
12.4.5 Gender-specific Distribution of Venous Ulcers in Germany
12.4.6 Age-specific Distribution of Venous Ulcers in Germany
12.5 France
12.5.1 Prevalent Cases of Venous Ulcers in France
12.5.2 Diagnosed Prevalent Cases of Venous Ulcers in France
12.5.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in France
12.5.4 Type-specific Distribution of Venous Ulcers in France
12.5.5 Gender-specific Distribution of Venous Ulcers in France
12.5.6 Age-specific Distribution of Venous Ulcers in France
12.6 Italy
12.6.1 Prevalent Cases of Venous Ulcers in Italy
12.6.2 Diagnosed Prevalent Cases of Venous Ulcers in Italy
12.6.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Italy
12.6.4 Type-specific Distribution of Venous Ulcers in Italy
12.6.5 Gender-specific Distribution of Venous Ulcers in Italy
12.6.6 Age-specific Distribution of Venous Ulcers in Italy
12.7 Spain
12.7.1 Prevalent Cases of Venous Ulcers in Spain
12.7.2 Diagnosed Prevalent Cases of Venous Ulcers in Spain
12.7.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Spain
12.7.4 Type-specific Distribution of Venous Ulcers in Spain
12.7.5 Gender-specific Distribution of Venous Ulcers in Spain
12.7.6 Age-specific Distribution of Venous Ulcers in Spain
12.8 United Kingdom
12.8.1 Prevalent Cases of Venous Ulcers in the United Kingdom
12.8.2 Diagnosed Prevalent Cases of Venous Ulcers in the United Kingdom
12.8.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in the United Kingdom
12.8.4 Type-specific Distribution of Venous Ulcers in the United Kingdom
12.8.5 Gender-specific Distribution of Venous Ulcers in the United Kingdom
12.8.6 Age-specific Distribution of Venous Ulcers in the United Kingdom
12.9 Japan
12.9.1 Prevalent Cases of Venous Ulcers in Japan
12.9.2 Diagnosed Prevalent Cases of Venous Ulcers in Japan
12.9.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Japan
12.9.4 Type-specific Distribution of Venous Ulcers in Japan
12.9.5 Gender-specific Distribution of Venous Ulcers in Japan
12.9.6 Age-specific Distribution of Venous Ulcers in Japan

13 Unmet Needs

14 Emerging Drugs

14.1 Key Competitors
14.2 Allogeneic ABCB5-positive Stem Cells: RHEACELL GmbH
14.2.1 Product Description
14.2.2 Other Developmental Activities
14.2.3 Safety and Efficacy
14.2.4 Product Profile
14.3 EscharEx: MediWound
14.3.1 Product Description
14.3.2 Other Developmental Activities
14.3.3 Clinical Development
14.3.4 Safety and Efficacy
14.3.5 Product Profile
14.4 TTAX01: Tissue Tech
14.4.1 Product Description
14.4.2 Other Development Activities
14.4.3 Clinical Development
14.4.4 Product Profile

15 Market Access and Reimbursement

15.1 United States
15.2 EU5 Countries
15.2.1 Italy
15.2.2 Germany
15.2.3 United Kingdom
15.2.4 France
15.2.5 Spain
15.3 Japan

16 Chronic venous ulceration (CVU): Seven Major Market Analysis

16.1 Key Findings
16.2 Market Size of Chronic Venous Ulceration (CVU) in the 7MM
16.3 7MM Market Outlook
16.1 United States Market Size
16.1.1 Total Market size of Chronic Venous Ulceration
16.1.2 Market Size by Current Therapies
16.1.3 Market Size by Emerging Therapies
16.2 EU5 Market Size
16.3 Germany
16.3.1 Total Market size of Chronic Venous Ulceration
16.3.2 Market Size by Current Therapies
16.3.3 Market Size by Emerging Therapies
16.4 France
16.4.1 Total Market size of Chronic Venous Ulceration
16.4.2 Market Size by Current Therapies
16.4.3 Market Size by Emerging Therapies
16.5 Italy
16.5.1 Total Market size of Chronic Venous Ulceration
16.5.2 Market Size by Current Therapies
16.5.3 Market Size by Emerging Therapies
16.6 Spain
16.6.1 Total Market size of Chronic Venous Ulceration
16.6.2 Market Size by Current Therapies
16.6.3 Market Size by Emerging Therapies
16.7 United Kingdom
16.7.1 Total Market size of Chronic Venous Ulceration
16.7.2 Market Size by Current Therapies
16.7.3 Market Size by Emerging Therapies
16.8 Japan Market Size
16.8.1 Total Market size of Chronic Venous Ulceration
16.8.2 Market Size by Current Therapies
16.8.3 Market Size by Emerging Therapies

17 Case Reports

18 Market Drivers

19 Market Barriers

20 KOL Reviews

21 Appendix

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

List of Tables
Table 1: Summary of CVU, Market, Epidemiology and Key Events (2017-2030)
Table 2: Basic CEAP classification system
Table 3: Antibiotic treatments for chronic venous ulcers
Table 4:Functional categories, classifications, characteristics, and Healthcare Common Procedure Coding System classification of wound dressings with active chemical, enzymatic, biologic, or antimicrobial components
Table 5: Surgical treatments for chronic venous ulcers
Table 6: Total Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Table 7: Diagnosed Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Table 8: Diagnosed Prevalent Population of Chronic Venous Ulcers in the 7MM (2017-2030)
Table 9: Prevalence of Venous Ulcers in the US (2017-2030)
Table 10: Diagnosed Prevalence of Venous Ulcers in the US (2017-2030)
Table 11: Diagnosed Prevalent Cases of Venous Leg Ulcers in the US (2017-2030)
Table 12: Type-specific Distribution of Venous Ulcers in the US (2017-2030)
Table 13: Gender-specific Distribution of Venous Ulcers in the US (2017-2030)
Table 14: Age-specific Distribution of Venous Ulcers in the US (2017-2030)
Table 15: Prevalence of Venous Ulcers in Germany (2017-2030)
Table 16: Diagnosed Prevalence of Venous Ulcers in Germany (2017-2030)
Table 17: Diagnosed Prevalent Cases of Venous Leg Ulcers in Germany (2017-2030)
Table 18: Type-specific Distribution of Venous Ulcers in Germany (2017-2030)
Table 19: Gender-specific Distribution of Venous Ulcers in Germany (2017-2030)
Table 20: Age-specific Distribution of Venous Ulcers in Germany (2017-2030)
Table 21: Prevalence of Venous Ulcers in France (2017-2030)
Table 22: Diagnosed Prevalence of Venous Ulcers in France (2017-2030)
Table 23: Diagnosed Prevalent Cases of Venous Leg Ulcers in France (2017-2030)
Table 24: Type-specific Distribution of Venous Ulcers in France (2017-2030)
Table 25: Gender-specific Distribution of Venous Ulcers in France (2017-2030)
Table 26: Age-specific Distribution of Venous Ulcers in France (2017-2030)
Table 27: Prevalence of Venous Ulcers in Italy (2017-2030)
Table 28: Diagnosed Prevalence of Venous Ulcers in Italy (2017-2030)
Table 29: Diagnosed Prevalent Cases of Venous Leg Ulcers in Italy (2017-2030)
Table 30: Type-specific Distribution of Venous Ulcers in Italy (2017-2030)
Table 31: Gender-specific Distribution of Venous Ulcers in Italy (2017-2030)
Table 32: Age-specific Distribution of Venous Ulcers in Italy (2017-2030)
Table 33: Prevalence of Venous Ulcers in Spain (2017-2030)
Table 34: Diagnosed Prevalence of Venous Ulcers in Spain (2017-2030)
Table 35: Diagnosed Prevalent Cases of Venous Leg Ulcers in Spain (2017-2030)
Table 36: Type-specific Distribution of Venous Ulcers in Spain (2017-2030)
Table 37: Gender-specific Distribution of Venous Ulcers in Spain (2017-2030)
Table 38: Age-specific Distribution of Venous Ulcers in Spain (2017-2030)
Table 39: Prevalence of Venous Ulcers in the UK (2017-2030)
Table 40: Diagnosed Prevalence of Venous Ulcers in the UK (2017-2030)
Table 41: Diagnosed Prevalent Cases of Venous Leg Ulcers in the UK (2017-2030)
Table 42: Type-specific Distribution of Venous Ulcers in the UK (2017-2030)
Table 43: Gender-specific Distribution of Venous Ulcers in the UK (2017-2030)
Table 44: Age-specific Distribution of Venous Ulcers in the UK (2017-2030)
Table 45: Prevalence of Venous Ulcers in Japan (2017-2030)
Table 46: Diagnosed Prevalence of Venous Ulcers in Japan (2017-2030)
Table 47: Diagnosed Prevalent Cases of Venous Leg Ulcers in Japan (2017-2030)
Table 48: Type-specific Distribution of Venous Ulcers in Japan (2017-2030)
Table 49: Gender-specific Distribution of Venous Ulcers in Japan (2017-2030)
Table 50: Age-specific Distribution of Venous Ulcers in Japan (2017-2030)
Table 51: Comparison of emerging therapies under development
Table 52: ABCB5-positive Stem Cells, Clinical Trial Description, 2020
Table 53: EscharEx, Clinical Trial Description, 2020
Table 54: TTAX01, Clinical Trial Description, 2020
Table 55: Seven Major Market Size of CVU in USD Million (2017-2030)
Table 56: Total Market Size of CVU in the US, in USD Million (2017-2030)
Table 57: Market size of CVU by current therapies in the US, in USD Million (2017-2030)
Table 58: Market size of CVU by emerging therapies in the US, in USD Million (2017-2030)
Table 59: Total Market Size of CVU in Germany, in USD Million (2017-2030)
Table 60: Market size of CVU by current therapies in Germany, in USD Million (2017-2030)
Table 61: Market size of CVU by emerging therapies in Germany, in USD Million (2017-2030)
Table 62: Total Market Size of CVU in France, in USD Million (2017-2030)
Table 63: Market size of CVU by current therapies in France, in USD Million (2017-2030)
Table 64: Market size of CVU by emerging therapies in France, in USD Million (2017-2030)
Table 65: Total Market Size of CVU in Italy, in USD Million (2017-2030)
Table 66: Market size of CVU by current therapies in Italy, in USD Million (2017-2030)
Table 67: Market size of CVU by emerging therapies in Italy, in USD Million (2017-2030)
Table 68: Total Market Size of CVU in Spain, in USD Million (2017-2030)
Table 69: Market size of CVU by current therapies in Spain, in USD Million (2017-2030)
Table 70: Market size of CVU by emerging therapies in Spain, in USD Million (2017-2030)
Table 71: Total Market Size of CVU in the UK, in USD Million (2017-2030)
Table 72: Market size of CVU by current therapies in the UK, in USD Million (2017-2030)
Table 73: Market size of CVU by emerging therapies in the UK, in USD Million (2017-2030)
Table 74: Total Market Size of CVU in Japan, in USD Million (2017-2030)
Table 75: Market size of CVU by current therapies in Japan , in USD Million (2017-2030)
Table 76: Market size of CVU by emerging therapies in Japan, in USD Million (2017-2030)

List of Figures
Figure 1: Chronic venous ulceration (CVU) SWOT Analysis
Figure 2: Pathways from vein to ulcer
Figure 3: Total Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Figure 4: Diagnosed Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Figure 5: Diagnosed Prevalent Population of Chronic Venous Ulcers in the 7MM (2017-2030)
Figure 6: Prevalent Cases of Venous Ulcers in the US (2017-2030)
Figure 7: Diagnosed Prevalent Cases of Venous Ulcers in the US (2017-2030)
Figure 8: Diagnosed Prevalent Cases of Venous Leg Ulcers in the US (2017-2030)
Figure 9: Type-specific Distribution of Venous Ulcers in the US (2017-2030)
Figure 10: Gender-specific Distribution of Venous Ulcers in the US (2017-2030)
Figure 11: Age-specific Distribution of Venous Ulcers in the US (2017-2030)
Figure 12: Prevalent Cases of Venous Ulcers in Germany (2017-2030)
Figure 13: Diagnosed Prevalent Cases of Venous Ulcers in Germany (2017-2030)
Figure 14: Diagnosed Prevalent Cases of Venous Leg Ulcers in Germany (2017-2030)
Figure 15: Type-specific Distribution of Venous Ulcers in Germany (2017-2030)
Figure 16: Gender-specific Distribution of Venous Ulcers in Germany (2017-2030)
Figure 17: Age-specific Distribution of Venous Ulcers in Germany (2017-2030)
Figure 18: Prevalent Cases of Venous Ulcers in France (2017-2030)
Figure 19: Diagnosed Prevalent Cases of Venous Ulcers in France (2017-2030)
Figure 20: Diagnosed Prevalent Cases of Venous Leg Ulcers in France (2017-2030)
Figure 21: Type-specific Distribution of Venous Ulcers in France (2017-2030)
Figure 22: Gender-specific Distribution of Venous Ulcers in France (2017-2030)
Figure 23: Age-specific Distribution of Venous Ulcers in France (2017-2030)
Figure 24: Prevalent Cases of Venous Ulcers in Italy (2017-2030)
Figure 25: Diagnosed Prevalent Cases of Venous Ulcers in Italy (2017-2030)
Figure 26: Diagnosed Prevalent Cases of Venous Leg Ulcers in Italy (2017-2030)
Figure 27: Type-specific Distribution of Venous Ulcers in Italy (2017-2030)
Figure 28: Gender-specific Distribution of Venous Ulcers in Italy (2017-2030)
Figure 29: Age-specific Distribution of Venous Ulcers in Italy (2017-2030)
Figure 30: Prevalent Cases of Venous Ulcers in Spain (2017-2030)
Figure 31: Diagnosed Prevalent Cases of Venous Ulcers in Spain (2017-2030)
Figure 32: Diagnosed Prevalent Cases of Venous Leg Ulcers in Spain (2017-2030)
Figure 33: Type-specific Distribution of Venous Ulcers in Spain (2017-2030)
Figure 34: Gender-specific Distribution of Venous Ulcers in Spain (2017-2030)
Figure 35: Age-specific Distribution of Venous Ulcers in Spain (2017-2030)
Figure 36: Prevalent Cases of Venous Ulcers in the UK (2017-2030)
Figure 37: Diagnosed Prevalent Cases of Venous Ulcers in the UK (2017-2030)
Figure 38: Diagnosed Prevalent Cases of Venous Leg Ulcers in the UK (2017-2030)
Figure 39: Type-specific Distribution of Venous Ulcers in the UK (2017-2030)
Figure 40: Gender-specific Distribution of Venous Ulcers in the UK (2017-2030)
Figure 41: Age-specific Distribution of Venous Ulcers in the UK (2017-2030)
Figure 42: Prevalent Cases of Venous Ulcers in Japan (2017-2030)
Figure 43: Diagnosed Prevalent Cases of Venous Ulcers in Japan (2017-2030)
Figure 44: Diagnosed Prevalent Cases of Venous Leg Ulcers in Japan (2017-2030)
Figure 45: Type-specific Distribution of Venous Ulcers in Japan (2017-2030)
Figure 46: Gender-specific Distribution of Venous Ulcers in Japan (2017-2030)
Figure 47: Age-specific Distribution of Venous Ulcers in Japan (2017-2030)
Figure 48: Unmet Needs of CVU
Figure 49: Seven Major Market Size of CVU in USD Million (2017-2030)
Figure 50: Total Market Size of CVU in the US, USD Millions (2017-2030)
Figure 51: Market size of CVU by current therapies in the US, in USD Million (2017-2030)
Figure 52: Market size of CVU by emerging therapies in the US, in USD Million (2017-2030)
Figure 53: Total Market Size of CVU in Germany, USD Millions (2017-2030)
Figure 54: Market size of CVU by current therapies in Germany, in USD Million (2017-2030)
Figure 55: Market size of CVU by emerging therapies in Germany, in USD Million (2017-2030)
Figure 56: Total Market Size of CVU in France, USD Millions (2017-2030)
Figure 57: Market size of CVU by current therapies in France, in USD Million (2017-2030)
Figure 58: Market size of CVU by emerging therapies in France, in USD Million (2017-2030)
Figure 59: Total Market Size of CVU in Italy, USD Millions (2017-2030)
Figure 60: Market size of CVU by current therapies in Italy, in USD Million (2017-2030)
Figure 61: Market size of CVU by emerging therapies in Italy, in USD Million (2017-2030)
Figure 62: Total Market Size of CVU in Spain, USD Millions (2017-2030)
Figure 63: Market size of CVU by current therapies in Spain, in USD Million (2017-2030)
Figure 64: Market size of CVU by emerging therapies in Spain, in USD Million (2017-2030)
Figure 65: Total Market Size of CVU in the UK, USD Millions (2017-2030)
Figure 66: Market size of CVU by current therapies in the UK, in USD Million (2017-2030)
Figure 67: Market size of CVU by emerging therapies in the UK, in USD Million (2017-2030)
Figure 68: Total Market Size of CVU in Japan, USD Millions (2017-2030)
Figure 69: Market size of CVU by current therapies in Japan, in USD Million (2017-2030)
Figure 70: Market size of CVU by emerging therapies in Japan, in USD Million (2017-2030)
Figure 71: Market Drivers
Figure 72: Market Barriers of CVU

Key Companies
Rheacel
MediWound
Tissue Tech